Abstract: The instant disclosure describes methods for treating diseases and conditions of the central and peripheral nervous system by stimulating or increasing neurogenesis. The invention includes methods based on use of a 4-acylaminopyridine derivative to stimulate or activate the formation of new nerve cells.

Abstract: An electrochemical apparatus 1 permits electric-field-assisted fluidic assembly of objects 2 on a patterned silicon substrate 11 by means of electrical addressing. Charged objects 2 such as beads and live cells are moved electrokinetically, like as in electrophoresis, through a solution, typically water 3, towards a micro-patterned charged semiconductor electrode, such as a silicon electrode 11 patterned with silicon dioxide, silicon nitride or agarose gel. The charged objects 2 are thus localized and assembled, most typically into arrays of multiple or single particles, in accordance with the patterning of the electrode 11. Correlating with theoretical predictions, negatively charged polystyrene beads of 20 ?m diameter, or live mammalian cells of 20-30 ?m diameter, can be assembled and disassembled on 100 ?m feature size micro-patterned substrates by means of electrical addressing.

Abstract: The instant disclosure describes methods for treating diseases and conditions of the central and peripheral nervous system by stimulating or increasing neurogenesis. The disclosure includes compositions and methods based on use of one or more biguanides in combination with one or more GSK3-? agents, to stimulate or activate the formation of new nerve cells.

Abstract: The instant disclosure describes methods for treating diseases and conditions of the central and peripheral nervous system by stimulating or increasing neurogenesis. The disclosure includes compositions and methods based on use of modafinil, optionally in combination with one or more other neurogenic agents, to stimulate or activate the formation of new nerve cells.

Abstract: The present disclosure describes methods for treating diseases and conditions of the central and peripheral nervous system by stimulating or increasing neurogenesis. The disclosure includes compositions and methods based on use of melatonin or other melatoninergic agent, optionally in combination with one or more other neurogenic agents, to stimulate or activate the formation of new nerve cells.

Abstract: The present disclosure describes compositions and methods for treating diseases and conditions of the central and peripheral nervous system by stimulating or increasing neurogenesis. The disclosure includes compositions and methods based on use of a melanocortin receptor (MCR) modulating agent, optionally in combination with one or more other neurogenic agents, to stimulate or activate the formation of new nerve cells.

Abstract: The instant disclosure describes methods for treating diseases and conditions of the central and peripheral nervous system including by stimulating or increasing neurogenesis, neuroproliferation, and/or neurodifferentiation. The disclosure includes compositions and methods based on use of a peroxisome proliferator-activated receptor (PPAR) agent, optionally in combination with one or more other neurogenic agents, to stimulate or increase a neurogenic response and/or to treat a disease.

Abstract: The instant disclosure describes methods of treating diseases and conditions of the central and peripheral nervous system including by stimulating or increasing neurogenesis, neuroproliferation, and/or neurodifferentiation. The disclosure includes compositions and methods based on use of an HMGCR modulating agent, optionally in combination with one or more other neurogenic agents, to stimulate or increase a neurogenic response and/or to treat disease.

Abstract: The instant disclosure describes compositions and methods for treating diseases and conditions of the central and peripheral nervous system. The disclosure includes compositions and methods based on use of a 4-acylaminopyridine derivative in combination with one or more other neurogenic agents. One 4-acylaminopyridine derivative is MKC-231.

Abstract: The instant disclosure describes methods for treating diseases and conditions of the central and peripheral nervous system by stimulating or increasing neurogenesis. The disclosure includes compositions and methods based on use of a 5HTR agent, optionally in combination with one or more other neurogenic agents, to stimulate or activate the formation of new nerve cells.

Abstract: The instant disclosure describes methods for treating diseases and conditions of the central and peripheral nervous system by stimulating or increasing neurogenesis. The disclosure includes compositions and methods based on use of melatonin or other nootropic agent, optionally in combination with one or more other neurogenic agents, to stimulate or activate the formation of new nerve cells.

Abstract: The instant disclosure describes methods for treating diseases and conditions of the central and peripheral nervous system by stimulating or increasing neurogenesis. The disclosure includes compositions and methods based on use of a PDE agent, optionally in combination with one or more other neurogenic agents, to stimulate or activate the formation of new nerve cells.

Abstract: The instant disclosure describes methods for treating diseases and conditions of the central and peripheral nervous system by stimulating or increasing neurogenesis. The disclosure includes compositions and methods based on use of a GABA agent, optionally in combination with one or more other neurogenic agents, to stimulate or activate the formation of new nerve cells.

Abstract: The instant disclosure describes methods for treating diseases and conditions of the central and peripheral nervous system by stimulating or increasing neurogenesis. The disclosure includes compositions and methods based on an HDac inhibitory agent alone or in combination with another neurogenic agent to stimulate or activate the formation of new nerve cells.

Abstract: The instant disclosure describes methods for treating diseases and conditions of the central and peripheral nervous system by stimulating or increasing neurogenesis. The disclosure includes compositions and methods based on muscarinic receptor modulation, such as via inhibition of acetylcholine esterase (AChE) activity, alone or in combination with another neurogenic agent to stimulate or activate the formation of new nerve cells.

Abstract: Methods and tools for identifying agents and conditions that modulate neurogenesis are disclosed. The disclosure also relates to methods and tools for identifying populations of neural stem cells suitable for transplantation.

Abstract: An electrochemical apparatus 1 permits electric-field-assisted fluidic assembly of objects 2 on a patterned silicon substrate 11 by means of electrical addressing. Charged objects 2 such as beads and live cells are moved electrokinetically, like as in electrophoresis, through a solution, typically water 3, towards a micro-patterned charged semiconductor electrode, such as a silicon electrode 11 patterned with silicon dioxide, silicon nitride or agarose gel. The charged objects 2 are thus localized to and assembled, most typically into arrays of multiple or single particles, in accordance with the patterning of the electrode 11. Correlating with theoretical predictions, negatively charged polystyrene beads of 20 ?m diameter, or live mammalian cells of 20-30 ?m diameter, can be assembled and disassembled on 100 ?m feature size micro-patterned substrates by means of electrical addressing.

Abstract: A system and methods for identifying sequence diversity in a gene or expressed sequence is disclosed wherein hybridization differences arising from polymorphic bases in analogous expressed sequences are identified between two or more nucleotide populations. By scaling the hybridization data to account for differences in abundance and observed intensity, sequence diversity can be identified in a highly specific and sensitive manner. Data confidence levels are also accounted for to increase the accuracy of the sequence diversity determination. The invention can be applied to both newly collected gene expression data and archived data to generate valuable insight into polymorphic behavior within complex nucleotide populations.

Abstract: The present disclosure relates to an inbred non-human transgenic animal having a multimeric nuclear hormone receptor, comprising a thyroid hormone receptor subunit and a nuclear hormone receptor subunit, wherein either or both the thyroid hormone receptor subunit and a nuclear hormone receptor subunits are mutated such that expression of said multimeric nuclear hormone receptor results in a measurable phenotype. The disclosure also contemplates methods of making inbred non-human transgenic animals. Methods of using the disclosed inbred non-human transgenic animals as models for various diseases and for screening small molecules that are determined to be efficacious in the treatment of such diseases are also disclosed.